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Abstract:   
 This is the final write-up for an honors research project for the University of Akron 
Williams Honors College. Synthesis of novel imidazolium salts was conducted. Following 
synthesis of imidazolium salts, the stability of the compound was tested at 37°C over a 72-hour 
period to give preliminary information about drug stability in vivo. 2D NMR was also conducted 
to confirm the structure of TPP-1. The student wrote an experimental protocol for the use of 
C57BL/6 mice and performed the online CITI training by the IRB to prepare to work with 
animals in a study of the antitumor properties of imidazolium salts in mice. Plausible 
physiological mechanisms by which the imidazolium cations exert their anti-tumor effects are 
discussed; current evidence demonstrates that imidazolium cations may be targeting the 
mitochondria of cancer cells. 
Introduction: 
Lung cancer is a deadly disease. The American Cancer Society predicts that about 
230,000 new cases of lung cancer will develop and about 150,000 deaths will be caused by lung 
cancer in the United States in 2019 (American Cancer Society, 2019). Current medical 
treatments for lung cancer have low success rates (Thatcher et al., Sandler et al., Garon et al., 
Brahmer et al., Borghaei et al., Reck et al., Yang et al.), so it is important to perform studies to 
search for treatments that have higher success rates or increase length of overall survival after 
treatment. The problems associated with current cancer treatments include resistance to 
treatment, increased risk of infection, and side effects, such as nausea, vomiting, pain, 
neuropathy, hair loss, anemia, bleeding, and appetite loss (American Cancer Society, 2016). The 
data collected during this project will contribute to the development of new treatment options for 
cancer, which could improve quality of life and save the lives of non-small cell lung cancer 
patients. Imidazolium salts are currently being researched for their potential antitumor properties.  
In this project, a novel imidazolium salt (1,3-bis(naphthalen-2-ylmethyl)-2-phenyl-
benzimidazolium bromide) was synthesized. We confirmed synthesis of this product with 1H 
NMR and 13C NMR. A stability study of TPP-1 (1,3-bis(naphthalen-2-ylmethyl)-2-(2-
(triphenylphosphonio)ethyl)-benzoimidazolium dibromide) was also performed. This stability 
study consisted of 1H NMR and 31P NMR at time points 0, 2, 4, 8, 24, 48, and 72 hours to 
observe the degradation of this compound over time. The sample was held at 37°C throughout 
the course of the 72-hour study to mimic body temperature. 2D NMR was performed to confirm 
structure of TPP-1. We also address data from NCI-60 cell line panels for TPP-1 and IS-121 and 
discuss the efficacy of these two compounds in vitro. An in vivo study was proposed to test the 
antitumor properties of the novel imidazolium salt TPP-1 on C57BL/6 mice. An experimental 
protocol for the use of animals was written by the student, and the student performed CITI 
training for use of animals. A brief overview of the proposed in vivo study is discussed. 
 
Mechanism of antitumor activity of imidazolium salts: 
Imidazolium cations are of current interest in compounds with antitumor properties, 
because it has been shown that imidazolium cations target the mitochondria of cancer cells more 
than that of non-cancerous cells, leading to apoptosis in cancerous cells. The reason that 
imidazolium cations target cancer cells more than non-cancer cells is because cancer cells are 
more negatively-charged than non-cancer cells.  
In all cells, the mitochondrial matrix is negatively charged because during oxidative 
phosphorylation, H+ ions are pumped from the matrix into the intermembrane space, therefore 
hyperpolarizing the matrix. Although H+ will diffuse down their gradient from the 
intermembrane space into the matrix, which would have a depolarizing effect, the membrane 
does not actually become depolarized because H+ are continually pumped up their gradient into 
the intermembrane space by the respiratory chain complexes; this maintains the inner 
mitochondrial membrane in a hyperpolarized state (Forrest, 2015).  
The inner mitochondrial membrane of cancer cells is even more hyperpolarized than that 
of non-cancerous cells. This effect is especially exaggerated when the cancer cells are utilizing 
aerobic glycolysis. Because of the high rates of proliferation of cancer cells, these cells have high 
rates of aerobic glycolysis, and therefore, cancer cells have extreme hyperpolarization of the 
mitochondrial membrane potential.  The mitochondrial membrane potential of cancerous cells is 
about -220 mV, in comparison with about -140 mV in non-cancerous cells (Forrest, 2015). 
Because the inner mitochondrial membrane is negatively charged, delocalized lipophilic 
cations (such as imidazolium salts) can cross the cell membranes and are attracted to the 
negatively-charged mitochondrial matrix. As a result, an accumulation of delocalized lipophilic 
cations occurs in the matrix (Forrest, 2015). Because cancerous cells are more hyperpolarized 
than non-cancerous cells, delocalized lipophilic cations are more attracted to cancer cells than 
non-cancerous cells. According to Forrest in a 2015 article about charge differences in cancerous 
and noncancerous cells, “Using the Nernst equation, if the ΨIM of a cancer cell is 60 mV more 
hyperpolarised than that of a normal cell – which is within the range of observation [14, 18-19] – 
then a single charged [delocalized lipophilic cation] will accumulate 10 times more in the 
mitochondrial matrix of cancer cells than normal cells (T=300 K). Delocalized lipophilic cations 
with a double charge will accumulate 100 times more.” Therefore, delocalized lipophilic cations 
are quite selective for cancerous cells. By selectively targeting cancerous cells, delocalized 
lipophilic cations may be a cancer treatment that could reduce overall side effects due to 
decreasing damage in healthy cells. 
If the inner mitochondrial membrane starts to depolarize, the voltage-sensitive 
permeability transition pore can be opened and allow for the entrance of pre-apoptotic agents that 
will lead to apoptotic cell death (Forrest, 2015). Delocalized lipophilic cations may combat 
cancer cells because the accumulation of these cationic compounds in the mitochondria reduce 
the mitochondrial membrane potential and depolarize the membrane, thereby inducing the 
generation of reactive oxygen species, inhibiting ATP production, and overall disrupting the 
progress of cancer cell proliferation (Battogtokh et al., 2018). 
Cancer treatments that utilize delocalized lipophilic cations may be useful in combatting 
resistance to cancer treatments, which is a present problem with cancer treatments that target 
DNA. If a treatment targets a specific DNA sequence, the cancer cells can undergo mutations 
that will render the treatment unable to exert its effects on the DNA and its protein-coding 
abilities; therefore, DNA mutations can lead to resistance of cancer against DNA-targeting 
treatments (Forrest, 2015). Since delocalized lipophilic cation treatments target the strongly 
hyperpolarized mitochondria (rather than the DNA) to induce apoptosis, it seems that cancerous 
cells will be unable to develop resistance to this type of treatment.  
To test whether imidazolium salts exert their anti-cancer effects via a mitochondrial 
disruption mechanism, Debord et al. (2017) performed a JC-1 assay. JC-1 is a cationic dye; as a 
result of the negatively-charged mitochondrial matrix, this cationic dye is prone to accumulate in 
the mitochondria. Accumulations of the dye (due to its attraction to the negatively-charged inner 
mitochondrial membrane) lead to a red color in the mitochondria and green in the cytosol. 
However, if the mitochondrial membrane potential is disrupted, aggregations of the dye do not 
occur, and imaging therefore shows green with little to no red fluorescence; instead, only green 
fluorescence is observed (Debord et al., 2017). In cancerous cell lines, cells treated with 
imidazolium salts showed very little red fluorescence in the JC-1 assay, whereas the control 
(non-cancerous) cells showed the expected, non-disrupted red fluorescence in the mitochondria 
and green fluorescence in the cytosol (Debord et al., 2017). This suggests that the imidazolium 
salts had successfully disrupted the mitochondrial membrane potential of the cancerous cells, 
supporting the hypothesis that the mechanism of antitumor activity of imidazolium salts is by 
disruption of the hyperpolarized mitochondrial membrane potential.  
Synthesis of 2-phenylbenzimidazole and 1,3-bis(naphthalen-2-ylmethyl)-2-phenyl-
benzimidazolium bromide 
The synthesis of our product consisted of multiple steps. First, 2-phenylbenzimidazole 
was synthesized (Figure 1), and NMR was utilized to confirm synthesis (Figure 2). Once 
formation of this product was verified, we continued our reaction to add on substituents and 
synthesize 1,3-bis(naphthalen-2-ylmethyl)-2-phenylbenzimidazolium bromide (Figure 3). Again, 
we confirmed synthesis with NMR (Figure 4, Figure 5). 
Synthesis of 2-phenyl-benzimidazole: 
 To synthesize 2-phenyl-benzimidazole, 0.998 grams of o-phenylenediamine, 945 μL of 
benzaldehyde, and 10 mL dry DMF were placed into a 50 mL round bottom flask. The mixture 
was heated to 145ºC and stirred for 12 hours. The reaction was poured into a 50 mL Erlenmeyer 
flask, and a yellow precipitate formed. The precipitate was collected via vacuum filtration. The 
product was washed with ether and collected via vacuum filtration, which yielded 1.015 grams of 
pale, yellow solid. This was a 56% yield. 
  
Figure 1. Synthesis of 2-phenyl-benzimidazole  
Figure 2. 2-phenylbenzimidazole 1H-NMR (300 MHz; DMSO-d6): δ  12.91 (s, 1H), 8.20-8.17 (m, 2H), 
7.58-7.47 (m, 5H), 7.20 (dd, J = 6.0, 2.3 Hz, 2H). 
 
 
 
 
 
Synthesis of 1,3-bis(naphthalen-2-ylmethyl)-2-phenyl-benzimidazolium bromide:  
For the synthesis of 1,3-bis(naphthalen-2-ylmethyl)-2-phenyl-benzimidazolium bromide, 
1.015 g of 2-phenyl-benzimidazole from the previous reaction, 350 mg KOH, and 10 mL dry 
acetonitrile were put into a 50 mL round bottom flask and heated at reflux with stirring for 30 
minutes. After this period of reflux with stirring, 1.19 g of 2-(bromomethyl)-naphthalene was 
added and heated at reflux with stirring for 24 hours. The solution was filtered hot to remove 
KBr and volatiles were removed to give an orange oil. NMR showed a mono-substituted product. 
After confirming synthesis of the mono-substituted product, we added 1.19 g of 2-
(bromomethyl)-naphthalene and 10 mL dry acetonitrile to the reaction mixture and heated to 
reflux with stirring for about 16 hours. Volatiles were removed, the product was recrystallized in 
ethanol, and the product was collected by vacuum filtration. The solid was washed with ether 
and collected by vacuum filtration to give 1.43 g of white solid, which was a 49% yield. 
 
 
 
Figure 3. Synthesis of 1,3-bis(naphthalen-2-ylmethyl)-2-phenyl-benzimidazolium bromide 
  
Figure 4. 1,3-bis(naphthalen-2-ylmethyl)-2-phenyl-benzimidazolium bromide 13C-NMR (300 
MHz; DMSO-d6) 
 Figure 5. 1,3-bis(naphthalen-2-ylmethyl)-2-phenyl-benzimidazolium bromide 1H-NMR (300 MHz; 
DMSO-d6): δ  8.10 (dd, J = 6.3, 3.1 Hz, 2H), 8.04-8.01 (m, 2H), 7.92-7.89 (m, 4H), 7.86-7.83 (m, 2H), 
7.78-7.74 (m, 3H), 7.68 (dt, J = 6.5, 3.4 Hz, 4H), 7.53-7.50 (m, 4H), 7.38 (dd, J = 8.5, 1.6 Hz, 2H), 5.85 
(s, 4H). 
 
Stability Study of TPP-1 
The stability of the imidazolium salt TPP-1 was studied over a period of 3 days.  
To prepare the sample for NMR studies, 10 mg of TPP-1 was dissolved in a solution of 50% 
DMSO d6 / D2O (350 μL DMSO in 350 μL D2O).  
1H and 31P NMR were obtained (Figure 6, Figure 7).  The NMR of the sample was 
collected at time points 0, 2, 4, 8, 24, 48, and 72 hours.  The sample was heated in the NMR 
warmer at 37°C to mimic body temperature.  A thermometer was placed into one of the slots of 
the NMR warmer to confirm temperature.  
Before putting a compound into an animal or human body, it is important to understand 
how it will be absorbed, distributed in the body (which organs it goes to), metabolism of the 
compound, and elimination (how it is cleared from the body). The stability study was performed 
as part of understanding drug stability in the animal; therefore, the sample of TPP-1 was held at 
37ºC to mimic body temperature. NMR was taken at time points 0, 2, 4, 8, 24, 48, and 72 hours 
in order to provide a preliminary look at how this product may break down over time in the 
body. 
Figure 6. TPP-1 1H-NMR (300 MHz; DMSO-d6) at 0, 2, 4, 8, 24, 48, and 72 hours: δ  7.89 (dd, J 
= 6.3, 3.1 Hz, 2H), 7.67-7.55 (m, 14H), 7.41-7.38 (m, 6H), 7.31 (td, J = 7.9, 3.5 Hz, 7H), 7.11 
(dd, J = 8.6, 1.3 Hz, 2H), 6.85 (dd, J = 12.9, 7.5 Hz, 6H), 5.91 (s, 4H), 3.68-3.64 (m, 2H), 2.92-
2.88 (m, 2H), 0.89-0.79 (m, 2H). 
 
 
 
Figure 7. TPP-1 31P-NMR (300 MHz; DMSO-d6) at 0, 2, 4, 8, 24, 48, and 72 hours. 
 
2D NMR Experiments 
A COSY 2D NMR spectrum was obtained to further confirm the structure of TPP-1 
(Figure 8). COSY 2D NMR correlates the protons to one another through one bond coupling.  
The COSY spectrum of TPP-1 does not offer much detail other than the coupling of the alkyl 
protons at 4.02, 3.97, and 1.90 ppm (Figure 9).  The proton resonances at 4.02 and 3.97 are too 
close together to determine significant coupling. This data does show that the alkyl protons 
around 4 ppm are coupled to the multiplet at 1.90 ppm (Figure 9).  The resonance at 1.90 ppm 
was presumed to be the middle alkyl in the propanol chain. 
Since the COSY NMR did not provide much information about the structure of TPP-1, an 
HSQC 2D NMR (1H – 13C) was obtained (Figure 10). The results of this experiment were used to 
determine that the alkyl closest to the phosphorous was the multiplet at 3.97 ppm in the 1H NMR 
which correlated to the resonance at 20.1 ppm (Figure 10).  In addition, a strange phenomenon 
was observed with the alkyl in the middle of the propyl chain.  This resonance was largely split 
due to coupling to phosphorus in the 1H NMR, but in the 13C little splitting was observed.  
Additionally, the resonance for the carbon and protons directly bound by to the imidazole 
nitrogen were also contradicting one another.  The resonance in the 1H NMR at 4.02 ppm was a 
slightly broadened triplet, but in the 13C a doublet carbon resonance at 24.2 ppm was shown to be 
correlating to this signal (Figure 10).  We were unable to explain this result. In addition to the 
alkyl data, the HSQC experiment also provided important information about the aromatic carbon 
resonances.  Although the 1H NMR showed less discernable structural data, all carbon aromatic 
resonances with an attached proton were assigned when 1H NMR data was combined with 13C 
NMR.  Commonly, the carbon resonance directly bound to phosphorus appears at 118 ppm with 
a large J-coupling (Kaiser, et al. 2006). The aromatic carbon bound directly to phosphorus was 
suspected to be at 117.6 ppm with a J-coupling of 86 Hz, because it was the only resonances at 
the lower aromatic range with no protons correlated to the signal. 
 In addition, another HSQC experiment was conducted to determine the correlation 
between 1H and 31P (Figure 11).  The interactions of protons to other nuclei in an HSQC 
experiment are commonly one-bond coupling, but due to the larger coupling constants of 1H – 
31P, some two-bond coupling was observed.  The correlation experiment was used to determine 
which protons were directly adjacent to the phosphorus atom.  It was determined that the proton 
resonance at 3.97 ppm was adjacent to the phosphorus and bonded to the carbon signal at 20.1 
ppm (Figure 11).  Furthermore, the aromatic protons that were two bonds away from the 
phosphorus were also observed, but little structural information was provided other than the 
aromatic protons of TPP-1 were at the large multiplet at 7.54 ppm (Figure 11).  Moreover, when 
the peak intensity of the 2-D spectrum was increased, the weak two bond coupling signal of the 
alkyl protons at 1.90 ppm was observed (Figure 11).  This confirmed the alkyl resonances at 3.97 
ppm (20.1 ppm) and 1.90 ppm (24.2 ppm) are bound one and two bonds away from the 
phosphorus, respectively. 
 
 
  
 
 
 
Figure 8. Structure of TPP-1 
 Figure 9. TPP-1 COSY 1H – 1H
 
Figure 10. HSQC 13C – 1H 
 
 Figure 11. HSQC 31P – 1H 
 
One-Dose Mean Graphs 
To interpret a one-dose mean graph, it is important to understand the meaning of the 
values in the graph. The value for growth rate is a comparison to the no-drug control. A 100% 
growth rate means that the experimental cell line experiences no inhibition relative to no-drug 
control. A cell line that has a 75% growth rate compared to control experiences 25% growth 
inhibition. A cell line that experiences a -75% growth rate experiences 75% lethality. A growth 
rate of -100% means that there was 100% lethality and all cells are dead. 
Cell lines treated with TPP-1 experienced a mean of 55.99% growth relative to the no-
drug control (Figure 12), whereas cell lines treated with IS-121 had a mean growth of 13.71% 
relative to the no-drug control (Figure 13). This means that cell lines treated with TPP-1 had a 
mean of 44.01% growth inhibition, whereas cell lines treated with IS-121 experienced a mean of 
86.29% growth inhibition. 
Specifically for non-small cell lung cancer cell lines treated with TPP-1, results showed 
34.82%-83.54% growth rates relative to control, with a mean of 59.33% (i.e. range of 16.46%-
65.18% growth inhibition, mean 40.67% growth inhibition; Figure 12). NSCLC cell lines treated 
with IS-121 exhibited a range of -24.30%-68.38% growth rate and a mean growth rate of 29.45% 
relative to control (31.62% inhibition to 24.30% lethality, with a mean of 70.55% growth 
inhibition; Figure 13). These results demonstrate that IS-121 is more effective at causing 
inhibition and lethality of NSCLC than TPP-1. 
These findings are summarized in table 1 and figures 12 and 13, below. 
 
 Table 1. Growth rate and growth inhibition of cell lines treated with TPP-1 and IS-121. Adapted 
from Developmental Therapeutics Program. Apr. 25, 2016 and Feb. 11, 2019. American Cancer 
Institute. 
 
 Mean growth rate 
relative to control 
Range of mean 
growth rate 
relative to control 
Mean growth 
inhibition  
Range of mean 
inhibition  
TPP-1, all cell 
lines 
55.99% 6.90%-100.09% 44.01% .09% growth-
93.1% 
inhibition 
IS-121, all cell 
lines 
13.71% (-97.80%)-
86.37% 
86.29% 13.63% 
inhibition to 
97.80% 
lethality 
TPP-1, NSCLC 59.33% 34.82%-83.54% 40.67% 16.46%-
65.18% 
IS-121, NSCLC 29.45% (-24.30%)-
68.38% 
70.55% 31.62% 
inhibition to 
24.30% 
lethality 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. One Dose Mean Graph for TPP-1. Reprinted from Developmental Therapeutics 
Program. Feb. 11, 2019. American Cancer Institute. 
  
 
Figure 13. One Dose Mean Graph for IS-121. Reprinted from Developmental Therapeutics 
Program. Apr. 25, 2019. American Cancer Institute. 
 
In vivo study concept in C57BL/6 mice 
Materials and methods: 
A protocol was written and CITI training from the IRB was performed by the student to 
be able to perform experiments with C57BL/6 mice. We planned to use TPP-1 as our 
experimental treatment against non-small cell lung cancer (NSCLC) in C57BL/6 mice, but the 
results from NCI-60 cell line screen in February 2019 by the Developmental Therapeutics 
showed that TPP-1 is not as effective at inhibiting cancer cell growth or causing lethality as other 
compounds (Figure 12, Figure 13). The compound IS-121 has produced results for the one-dose 
mean graph that show that IS-121 has stronger properties of inhibition and lethality in cancer cell 
lines (Figure 2). Therefore, it was deemed inhumane and unethical to use TPP-1 in experimental 
studies using animals due to the undue harm and suffering they would undergo for testing of a 
compound with only meager anti-tumor properties in comparison with other compounds. The 
plan for the in vivo experiments in C57BL/6 mice is described in detail below because of its 
future applications; other antitumor compounds could be tested using the procedures described 
below. 
 According to the protocol written by the student, the in vivo experiment would consist of 
an experimental group of C57 BL/6 mice, which receives the imidazolium salt treatment, and a 
control group of C57 BL/6 mice, which receives a placebo saline solution. The C57BL/6 mice 
would receive Lewis Lung Carcinoma (LLC) cells via subcutaneous injection on the back 
(Kellar, et al., 2015). Tumor growth would be monitored for 2 weeks. The tumor would be 
excised at 14 days, which consistently leads to metastasis (Gómez-Cuadrado, 2017). After tumor 
excision, the experimental and control groups would begin receiving their respective treatments 
and would receive these treatments for 2 weeks. During this time, the size of the tumors would 
be measured with calipers. After the period of 2 weeks of treatment, during which the mice 
receive the imidazolium salt treatment or saline solution, the mice would be euthanized and 
tumor size and weight, as well as lung histology, would be measured. 
Discussion and Conclusion: 
The qualities of interest in a novel compound that may be used as a drug are synthesis, 
stability, efficacy, and ADME (absorption, distribution, metabolism, and excretion). To confirm 
synthesis, we performed NMR of 2-phenylbenzimidazole and 1,3-bis(naphthalen-2-ylmethyl)-2-
phenyl-benzimidazolium bromide. The novel imidazolium salt synthesized in this study (1,3-
bis(naphthalen-2-ylmethyl)-2-phenyl-benzimidazolium bromide) has not yet been tested for its 
potential antitumor properties. In the future, this compound could be tested in an NCI-60 cell line 
panel to test for potential antitumor activity. 
Before putting a compound into an animal or human body, it is important to understand 
ADME: how it will be absorbed, where it will be distributed in the body (which organs it goes 
to), metabolism of the compound, and elimination (how it is cleared from the body). The stability 
study was performed as part of understanding drug stability in the animal; therefore, the sample 
of TPP-1 was held at 37°C to mimic body temperature. NMR was taken at time points 0, 2, 4, 8, 
24, 48, and 72 hours to provide a preliminary look at how this product may break down over 
time in the body, which relates to how the body may metabolize and eliminate this compound. 
TPP-1 compound was believed to have impressive tumor-targeting effects due to its 
double positive charge, but the NCI-60 cell line panels showed that TPP-1 is not as effective as 
IS-121 in inhibiting cancer cell growth. The reasons for the lack of efficacy of TPP-1 are not 
well understood and should be explored.  
 The in vivo study plan proposed by the student has future applications in that it could be 
utilized as a study model for other imidazolium cations to test for their antitumor properties in 
non-small cell lung cancer in C57BL/6 mice.  
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